GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, sales@genprice.com
Index / LCLabs / Bortezomib, Free Base / Product Detail : B-1408 Bortezomib, Free Base
Related keywords:
Sep
26th
#B-1408 Bortezomib, Free Base
| Price : | 201 | EUR |
| 228 | USD | |
| 156 | GBP | |
| 844 | Zloty | |
| 26910 | JPY | |
| 1551 | NOK | |
| 1661 | SEK | |
| 227 | CHF |
Product name : Bortezomib, Free Base
Catalog number : B-1408
Quantity: 25 mg
Availability: Yes
Supplier name : LCLabs
Data sheet: Ask more or other datasheet now !
Contact us about this product :
Our team will respond you as soon as possible !
We have also other products like : Bortezomib, Free Base
Related products : Bortezomib, Free Base
other names
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Related products : Bortezomib, Free Base
Gentaurpub
WP1625: Base excision repair
WP1787: Base Excision Repair
Related Genes :
[PSMB5 LMPX MB1 X] Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain epsilon chain) (Multicatalytic endopeptidase complex epsilon chain) (Proteasome chain 6) (Proteasome epsilon chain) (Proteasome subunit MB1) (Proteasome subunit X)
[PSMA3 HC8 PSC8] Proteasome subunit alpha type-3 (EC 3.4.25.1) (Macropain subunit C8) (Multicatalytic endopeptidase complex subunit C8) (Proteasome component C8)
[PSMA1 HC2 NU PROS30 PSC2] Proteasome subunit alpha type-1 (EC 3.4.25.1) (30 kDa prosomal protein) (PROS-30) (Macropain subunit C2) (Multicatalytic endopeptidase complex subunit C2) (Proteasome component C2) (Proteasome nu chain)
[CYP1A2] Cytochrome P450 1A2 (EC 1.14.14.1) (CYPIA2) (Cholesterol 25-hydroxylase) (Cytochrome P(3)450) (Cytochrome P450 4) (Cytochrome P450-P3)
[CYP2D6 CYP2DL1] Cytochrome P450 2D6 (EC 1.14.14.1) (CYPIID6) (Cholesterol 25-hydroxylase) (Cytochrome P450-DB1) (Debrisoquine 4-hydroxylase)
[CYP3A4 CYP3A3] Cytochrome P450 3A4 (EC 1.14.13.-) (1,8-cineole 2-exo-monooxygenase) (EC 1.14.13.157) (Albendazole monooxygenase) (EC 1.14.13.32) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cholesterol 25-hydroxylase) (EC 1.14.14.1) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1.14.13.67) (Taurochenodeoxycholate 6-alpha-hydroxylase) (EC 1.14.13.97)
[CYP2C9 CYP2C10] Cytochrome P450 2C9 (EC 1.14.13.-) ((R)-limonene 6-monooxygenase) (EC 1.14.13.80) ((S)-limonene 6-monooxygenase) (EC 1.14.13.48) ((S)-limonene 7-monooxygenase) (EC 1.14.13.49) (CYPIIC9) (Cholesterol 25-hydroxylase) (EC 1.14.99.38) (Cytochrome P-450MP) (Cytochrome P450 MP-4) (Cytochrome P450 MP-8) (Cytochrome P450 PB-1) (S-mephenytoin 4-hydroxylase)
[PRE2 DOA3 PRG1 YPR103W P8283.10] Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain subunit PRE2) (Multicatalytic endopeptidase complex subunit PRE2) (Proteasome component PRE2) (Proteinase YSCE subunit PRE2)
[PSMA6 PROS27] Proteasome subunit alpha type-6 (EC 3.4.25.1) (27 kDa prosomal protein) (PROS-27) (p27K) (Macropain iota chain) (Multicatalytic endopeptidase complex iota chain) (Proteasome iota chain)
[CYP1A1] Cytochrome P450 1A1 (EC 1.14.14.1) (CYPIA1) (Cytochrome P450 form 6) (Cytochrome P450-C) (Cytochrome P450-P1)
[CYP2C19] Cytochrome P450 2C19 (EC 1.14.13.-) ((R)-limonene 6-monooxygenase) (EC 1.14.13.80) ((S)-limonene 6-monooxygenase) (EC 1.14.13.48) ((S)-limonene 7-monooxygenase) (EC 1.14.13.49) (CYPIIC17) (CYPIIC19) (Cytochrome P450-11A) (Cytochrome P450-254C) (Mephenytoin 4-hydroxylase)
[PSMA7 HSPC] Proteasome subunit alpha type-7 (EC 3.4.25.1) (Proteasome subunit RC6-1) (Proteasome subunit XAPC7)
[PSMB6 LMPY Y] Proteasome subunit beta type-6 (EC 3.4.25.1) (Macropain delta chain) (Multicatalytic endopeptidase complex delta chain) (Proteasome delta chain) (Proteasome subunit Y)
[CYP2C8] Cytochrome P450 2C8 (EC 1.14.14.1) (CYPIIC8) (Cytochrome P450 IIC2) (Cytochrome P450 MP-12) (Cytochrome P450 MP-20) (Cytochrome P450 form 1) (S-mephenytoin 4-hydroxylase)
[PSMA4 HC9 PSC9] Proteasome subunit alpha type-4 (EC 3.4.25.1) (Macropain subunit C9) (Multicatalytic endopeptidase complex subunit C9) (Proteasome component C9) (Proteasome subunit L)
[PSMB3] Proteasome subunit beta type-3 (EC 3.4.25.1) (Proteasome chain 13) (Proteasome component C10-II) (Proteasome theta chain)
[PSMB1 PSC5] Proteasome subunit beta type-1 (EC 3.4.25.1) (Macropain subunit C5) (Multicatalytic endopeptidase complex subunit C5) (Proteasome component C5) (Proteasome gamma chain)
[PSMB7 Z] Proteasome subunit beta type-7 (EC 3.4.25.1) (Macropain chain Z) (Multicatalytic endopeptidase complex chain Z) (Proteasome subunit Z)
[PSMB4 PROS26] Proteasome subunit beta type-4 (EC 3.4.25.1) (26 kDa prosomal protein) (HsBPROS26) (PROS-26) (Macropain beta chain) (Multicatalytic endopeptidase complex beta chain) (Proteasome beta chain) (Proteasome chain 3) (HsN3)
[PSMA2 HC3 PSC3] Proteasome subunit alpha type-2 (EC 3.4.25.1) (Macropain subunit C3) (Multicatalytic endopeptidase complex subunit C3) (Proteasome component C3)
[PSMA5] Proteasome subunit alpha type-5 (EC 3.4.25.1) (Macropain zeta chain) (Multicatalytic endopeptidase complex zeta chain) (Proteasome zeta chain)
[PSMB2] Proteasome subunit beta type-2 (EC 3.4.25.1) (Macropain subunit C7-I) (Multicatalytic endopeptidase complex subunit C7-I) (Proteasome component C7-I)
[PRE10 PRC1 PRS1 YOR362C O6650] Probable proteasome subunit alpha type-7 (EC 3.4.25.1) (Macropain subunit C1) (Multicatalytic endopeptidase complex subunit C1) (Proteasome component C1) (Proteinase YSCE subunit 1)
[PRE3 YJL001W J1407] Proteasome subunit beta type-1 (EC 3.4.25.1) (Macropain subunit PRE3) (Multicatalytic endopeptidase complex subunit PRE3) (Proteasome component PRE3) (Proteinase YSCE subunit PRE3)
[Psmb5] Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain epsilon chain) (Multicatalytic endopeptidase complex epsilon chain) (Proteasome chain 6) (Proteasome epsilon chain) (Proteasome subunit X)
[PUP1 YOR157C] Proteasome subunit beta type-2 (EC 3.4.25.1) (Macropain subunit PUP1) (Multicatalytic endopeptidase complex subunit PUP1) (Proteasome component PUP1) (Proteinase YSCE subunit PUP1)
[PRE9 PRS5 YGR135W] Proteasome subunit alpha type-3 (EC 3.4.25.1) (Macropain subunit Y13) (Multicatalytic endopeptidase complex subunit Y13) (Proteasome component Y13) (Proteinase YSCE subunit 13)
[PRE1 YER012W] Proteasome subunit beta type-4 (EC 3.4.25.1) (Macropain subunit C11) (Multicatalytic endopeptidase complex subunit C11) (Proteasome component C11) (Proteinase YSCE subunit 11)
[PRE8 PRS4 YML092C] Proteasome subunit alpha type-2 (EC 3.4.25.1) (Macropain subunit Y7) (Multicatalytic endopeptidase complex subunit Y7) (Proteasome component Y7) (Proteinase YSCE subunit 7)
[PRE4 YFR050C] Proteasome subunit beta type-7 (EC 3.4.25.1) (Macropain subunit PRE4) (Multicatalytic endopeptidase complex subunit PRE4) (Proteasome component PRE4) (Proteinase YSCE subunit PRE4)
Bibliography :
[27659525] A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
[27659429] Stem Cell Transplantation In Multiple Myeloma.
[27655709] Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.
[27655642] Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
[27647864] Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
[27647225] Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
[27647123] Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
[27646819] Current treatments for renal failure due to multiple myeloma.
[27646591] pH/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy.
[27641423] Long-term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy.
Share this page:
Enter catalog number :
Favorites Pages:
No Favorits